Nirmatrelvir
未知生产厂商
Nirmatrelvir is an oral protease inhibitor with emergency use authorization for the treatment of mild-to-moderate COVID-19.
Nirmatrelvir is an oral protease inhibitor with emergency use authorization for the treatment of mild-to-moderate COVID-19.
Nirmatrelvir is an inhibitor of a cysteine residue in the 3C-like protease (3CL) of SARS-CoV-2. This cysteine is responsible to the activity of the 3CL of SARS-CoV-2 and potentially other members of the coronavirus family. The 3CL, also known as the main protease or non structural protein 5, is responsible for cleaving polyproteins 1a and 1ab. These polyproteins contain the 3CL itself, a papain-like (PL) cysteine protease, and 14 other nonstructural proteins. Without the activity of the 3CL, nonstructural proteins (including proteases) cannot be released to perform their functions, inhibiting viral replication.
In the US, Europe, and Canada, nirmatrelvir, in combination with ritonavir, is indicated for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. In Europe, this therapeutic indication is approved under conditional marketing authorization.
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
